谢小明 职务：乳腺科主任
职称：教授、主任医师、博士生导师
专长：从事肿瘤和乳腺癌医疗、教学和科研工作二十多年，在乳腺疾病的诊断和治疗方面拥有丰富的经验。在肿瘤分子生物学和靶向治疗分子机制方面研究成绩突出。

主要简介 详细介绍 预约挂号

中山大学肿瘤防治中心乳腺科主任,中山大学“****”引进人才，教授、博士研究生导师，华南肿瘤学国家重点实验室研究员，肿瘤生物技术研究室主任。美国M.D.Anderson癌症中心访问教授。2008年7月回国，与杨名添教授一起建立肿瘤防治中心乳腺科并担任主任。2009年9月建立华南肿瘤学国家重点实验室肿瘤生物技术研究室并担任主任，2009年与法国让佩林癌症中心建立中法癌症遗传学联合实验室并担任主任。目前是美国癌症研究协会（AACR）、美国临床癌症研究协会（ASCO）和美国基因治疗协会（ASGT）等会员，是《ChineseJournalofCancer》编辑部责任编委、美国《JournalofCancer》和《中华乳腺病杂志》责任编委，《CancerResearch》、《HumanGeneTherapy》和《AnnalsofSurgicalOncology》等多家杂志的审稿人。是国家自然科学基金委一审、二审专家和广东省自然科学基金委评审专家，广东省医学鉴定专家，广州市医疗事故技术鉴定专家。
医疗专长：
　　从事肿瘤和乳腺癌医疗、教学和科研工作二十多年，在乳腺疾病的诊断、手术和综合治疗方面拥有丰富的经验。在肿瘤分子生物学和靶向治疗分子机制方面研究成绩突出。

门诊时间：每周一、三上午。

　　中山大学肿瘤防治中心乳腺科主任，教授、主任医师、研究员、临床医学科学家、中山大学“****”引进人才、博士研究生导师、华南肿瘤学国家重点实验室PI、肿瘤生物技术研究室主任，美国M. D. Anderson癌症中心访问教授。2008年7月回国，与杨名添教授一起建立肿瘤防治中心乳腺科并担任主任。2009年9月建立华南肿瘤学国家重点实验室肿瘤生物技术研究室并担任主任，2009年与法国让佩林癌症中心建立中法癌症遗传学联合实验室并担任主任。目前是美国癌症研究协会（AACR）、美国临床癌症研究协会（ASCO）和美国基因治疗协会（ASGT）等会员，中国研究型医院学会乳腺专业委员会常委、中国抗癌协会肿瘤代谢委员会委员、中国健康促进会乳腺癌防治专家、卫生部医疗服务标准专业委员会专家。是《Global Journal of Epidemiology and Public Health》共同主编、 《Chinese Journal of Cancer》责任编委、美国《Journal of Tumor》副主编、《Journal of Cancer》和《中华乳腺病杂志》编委，《Cancer Research》、《Human Gene Therapy》和《Annals of Surgical Oncology》等多家杂志的审稿人。共发表论著170余篇，其中高水平论著150余篇，已获得或申请中国美国发明专利11项，研制临床前期产品10项，主持国家自然基金重点项目等30余项基金。是国家自然科学基金委一审和二审评审专家、教育部学位评审专家、中国博士后基金评审专家，广东省自然科学基金委评审专家，广东省医学鉴定专家，广州市医疗事故技术鉴定专家，广东省保健协会首席专家,获岭南名医和羊城好医生称号。

医疗专长：
　　从事肿瘤和乳腺癌医疗、教学和科研工作二十多年，在乳腺疾病的诊断、手术治疗、乳房重建和综合治疗方面拥有丰富的经验，在肿瘤分子生物学和靶向治疗分子机制研究方面成绩突出。

个人简介:
　　在中南大学湘雅医学院于1986年获医学学士学位，1994年获博士学位。1995-1997年在西班牙做博士后，1997-1999年在美国佛罗里达大学做博士后，1999-2003年在美国贝勒医学院任副研究员。2003-2008年在美国德州大学M. D. Anderson癌症中心任研究员，曾任分子和细胞肿瘤系转化研究课题组负责人，2010.9-2010.10在法国让佩林癌症中心合作研究。长期致力于癌症的基因调控，活体成像转基因动物模型和癌症的靶向基因治疗等方面研究，发展了多套新颖的对乳腺癌、胰腺癌、前列腺癌、卵巢癌、肝癌等多种癌症的靶向治疗策略和临床前期产品，与中国、美国、英国、日本、韩国及台湾地区的多家研究机构开展了广泛的交流和合作。
　　共发表论著170余篇，其中高水平论著150余篇(包括Cancer Cell， Nature Cell Biology，Science Signaling, Caner Research，Oncogene, Human Gene Therapy，Mol Cancer Therapeutics, Cancer Gene Therapy，Molecular Endocrinology，Digestive Diseases and Science等)。中英文专业书籍5本中各一章。其中以通讯作者/第一作者发表高水平论文90余篇，总影响因子380余分，1篇大于20（Cancer Cell，2007），以第一作者和共同作者发表论文总影响因子累计超600余分，他引共3800余次，其中第一作者论文单篇他引最高170余次，共同作者单篇他引最高500余次，H-Index 37。其中纳米颗粒介导的VISA系统靶向治疗胰腺癌的主要研究成果，发表在2007年7月份的Cancer Cell（IF值24.9）上。美国Science News上评论：“这种治疗癌症的方法是独一无二的，对癌症既有非常强的疗效又非常特异”。美国ABC电视台认为“这是癌症治疗的一个重大突破”。在论文发表后短期内，来自美国<<世界日报>>，以及中国、英国、俄国、德国、法国、西班牙、葡萄牙、意大利、荷兰、希腊、阿拉伯、韩国、日本等世界各地的多家科学杂志和新闻媒体对该成就进行了200多次报道和高度的评价。已获得中国美国发明专利11项，研制临床前期产品10项，其中1项已部分转让给美国Pfizer（辉瑞）制药公司，其中1项已经FDA批准，获许进入I期临床验证，已部分转让给台湾东洋制药公司。先后承担美国NIH、NCI重大课题5项。回国后，实施临床研究多项，主持中山大学II类引进人才基金、广州市科技计划、广东省自然基金、广东省科技计划、教育部博士点基金和国家自然基金面上和重点项目等30余项，经费3000余万元。

研究方向：
1.乳腺肿瘤的诊断及治疗，乳腺癌干细胞及纳米靶向治疗，乳腺肿瘤分子遗传学
2.肿瘤学和分子医学（肿瘤的发生发展机制，肿瘤早期诊断与生物治疗等）
3.细胞生物学
4.影像医学与生物医学工程
5.新型实验动物模型

发明专利：
1.谢小明等。One type of the innovative syringe.中国专利号（1994）: ZL **.X.
2.谢小明等。CANCER SPECIFIC PROMOTERS (Including breast cancer and ovarian cancer). USPT Patent. 癌症靶向基因治疗乳腺癌和卵巢癌. 美国专利申请号(11.2007): (AO-UTSC:995US)
3.谢小明等。CANCER SPECIFIC PROMOTERS (Including breast cancer, pancreatic cancer, prostate cancer). USPT Patent. 癌症靶向基因治疗乳腺癌, 胰腺癌和卵巢癌. 美国专利号（2010）：US**B2
4.谢小明等。EZC-prostate (a transgenic mouse model)(Disclosure). License to Pfizer (美国) 2005
5.谢小明等。一种可高效高特异灭杀乳腺癌细胞的药物。中国专利号:6.2。License to Guangzhou Pharmaceutical。
6.谢小明等。一种可高效在体内外转染基因的新型脂质体及其制备方法。中国专利申请号:0.1
7.谢小明等。一种在肿瘤细胞中高效高特异表达靶基因的载体T-VISA。中国专利申请号:1.X
8.谢小明等。一种可高效高特异灭杀乳腺癌细胞的药物T-VISA-PEA15。中国专利号:2.1
9.谢小明等。一种可高效高特异灭杀P53基因突变型乳腺癌细胞的T-VISA-miR34脂质体。中国专利申请号:0.X.
10.谢小明等。可稳定传代并保持原特性的乳腺癌干细胞系及其分离方法和应用。中国专利申请号:7.5
11.谢小明等。一种RNAcircEPSTII 及其在三阴乳腺癌上的应用。中国专利号:8.8.

主持研究基金：
1.国家自然基金重点项目（**）。EZC-乳腺癌干细胞转基因小鼠模型的建立及应用。200万.2011-2014.
2.国家自然基金面上项目（**）。POMC调控乳腺癌脑转移的作用及其机制研究。57万，2019-2022.
3.国家自然基金面上项目（**）。LGR5调控乳腺癌干细胞的休眠作用与机制研究。57万，2017-2020.
4.国家自然基金面上项目（**）。利用基因剔除小鼠研究miR-34a抑制乳腺癌的分子机制。75万.2015-2018.
5.国家自然基金面上项目（**）。VISA-miR-34a高效纳米系统靶向杀灭乳腺癌干细胞的作用及机制研究。65万.2013-2016.
6.广东省科技(2015B)。 一种可高效高特异杀灭乳腺癌的T-VISA-BikDD脂质体候选药物的研究。产学研合作项目省协同创新与平台环境建设专项基金。100万元。2015-17
7.广东省科技(2015B)。 一种高效抗乳腺癌T-VISA-PEA15脂质体候选药物的研究。社会发展领域 省协同创新与平台环境建设专项基金。100万元。2015-17
8.广州市民生科技项目。乳腺癌干细胞调控研究。广州市科技。100万，2016-2018.
9.中山大学肿瘤防治中心“临床科学家”基金。中山大学肿瘤防治中, 150万元。2015-17
10.中山大学肿瘤防治中心“临床研究”基金（308计划）。中山大学肿瘤防治中(2014-FXY-093), 80万元。2015-17
11.教育部高等学校博士学科点专项科研基金.乳腺癌干细胞的生物学特征及靶向治疗研究(078)。6万元（2009）.
12. 教育部回国人员启动基金. 乳腺癌靶向治疗。4万元 (2009).
13.广东省科技基金（2013B）。miR-34a抑制乳腺癌的作用及机制研究。10万元. 2014-2015.
14.广东省自然基金(9**0124)。应用“VISA”系统高效靶向杀灭乳腺癌干细胞的研究。5万元. 2009-2011.
15.广州市科技计划（2014J**）. VISA-miR-26a高效纳米颗粒抑制乳腺癌生长的机制研究。6万元。2013.7-2015.6
16.广州市科技计划. CD44-VISA-miR-200c高效纳米系统靶向杀灭乳腺癌干细胞的研究. 6万元。2010-7-2012.6
17.中山大学“985” 计划（**）。乳腺癌纳米靶向治疗机制。40万元, 2008-2010
18.中山大学. 2014年度“中山大学科研助手计划”.5万元
19.中心国际合作项目（美国M.D.Anderson癌症中心）。 Development of biomarkers to predict cetuximab resistance. 30万。2014-2016
20.华南肿瘤学重点实验室。含有1，8-萘酰亚胺单体的聚乙烯亚胺类非病毒基因载体的研究. 5万元. 2009-2010
21.华南肿瘤学重点实验室。前列腺癌细胞系肿瘤干细胞的分离、鉴定及其生物学特性和相关机制研究. 5万元. 2010-2011
22.华南肿瘤学重点实验室. 乳腺癌靶向治疗的研究. 15万元. 2010-2011
23.华南肿瘤学重点实验室. 乳腺癌靶向治疗的研究. 8万元. 2011-2012
24.华南肿瘤学重点实验室 乳腺癌靶向治疗的研究. 8万元. 2012-2013
25.华南肿瘤学重点实验室。 乳腺癌靶向治疗的研究. 15万元. 2013-2014
26.华南肿瘤学重点实验室 。乳腺癌靶向治疗的研究. 14.8万元. 2014-2015
27.华南肿瘤学重点实验室。乳腺癌靶向治疗的研究15万元，2015-2016
28.乳腺癌靶向治疗的研究。华南肿瘤学重点实验室。 15万元，2016-2017
29.华南肿瘤学重点实验室。乳腺癌靶向治疗的研究7万元，2017-2018
30.ZY001的化学合成及免疫原性评价。白云山中一药业有限公司合作基金, 15万元。2015-17
31.中国癌症基金会.中国乳腺癌临床流行病学多中心研究. 5.5万元. 2009.9-2010.12
32.Roche公司。血清her-2/neu 水平在乳腺癌中的价值研究. 5万元. 2010.9-2011.8
33.Co-Investigator, E1A Gene Therapy in Breast Cancer, RO1 CA058880, National Cancer Institute, NIH $261,000 ADC, 08/01/1997-01/31/2005.
34.Co-Investigator, “Targeting Breast Cancer-Specific Gene Therapy’ in NIH SPORE grant in Breast Cancer (5P50CA116199-03), 2005-2010.
35.Co-Investigator, “Development of Novel Gene Therapy for Pancreatic Cancer” in NIH SPORE grant in Pancreatic Cancer (P20 CA101936), P20 CA101936-01, NCI,NIH. $225,000 (ADC). 07/01/2003-06/30/2008.
36. Co-Investigator. “Development of E1A Gene Therapy in Ovarian Cancer” in NIH SPORE grant in Ovarian Cancer (5P50CA083639-08), 2005-2010.
37.Co-PI。 Ideal Development Award ($560,000), DOD (Department of Defense).USA. 2007.
38.Co-Investigator, Topfer Funds.2005-2010.
39.. Co-Investigator, M. D. Anderson Cancer Center Support Grant CA16672, 2005.
40.. Co-Investigator, NIH Grant R01-CA87569, Baylor College of Medicine, 2001-2006.

临床试验：
2003-Present 乳腺癌临床试验
　　1. E1A gene therapy for breast cancer; E1A 基因治疗乳腺癌
　　2. BikDD gene therapy for breast cancer. BikDD基因治疗乳腺癌 (prepared, under process of FDA)
　　3. E10A (Adenovirus expressing human endostatin) for recurrent breast cancer therapy (approved by SFDA)..
　　4. 喜滴克治疗乳腺癌的IV期临床试验, 2011-2012
2005-present 胰腺癌临床试验
　　1. BikDD gene therapy for pancreatic cancer. BikDD基因治疗胰腺癌 (prepared, under process of FDA)
2005-present 卵巢癌临床试
　　1. E1A gene therapy and SAHA for ovarian cancer. E1A 基因治疗和SAHA治疗卵巢癌
　　2. BikDD gene therapy for ovarian cancer. BikDD基因治疗卵巢癌 (prepared, under process of FDA)
308计划：三阴乳腺癌保乳和改良根治随机对照研究。2015.8
5010计划：ER（-α）/PR阴性/ER-β阳性乳腺癌术后辅助他莫昔芬内分泌治疗有效性和安全性的随机对照临床试验。2015.-2024

代表性论文
（第一和/或通讯作者(?)，92篇，影响因子385）：
1.Tang H, Chen B, Liu P, Xie X, He R, Zhang L, Huang X, Xiao X, Xie X(?).SOX8 acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. Carcinogenesis. 2019 Feb 27. pii: bgz034. doi: 10.1093/carcin/bgz034. [Epub ahead of print] （IF：5.072）
2.Zou Y, Zheng S, Xiao W, Xie X, Yang A, Gao G, Xiong Z, Xue Z, Tang H, Xie X(?).circRAD18 sponges miR-208a/3164 to promote triple-negative breast cancer progression through regulating IGF1 and FGF2 expression.Carcinogenesis. 2019 Apr 17. pii: bgz071. doi: 10.1093/carcin/bgz071. [Epub ahead of print] （IF：5.072）
3.Tang H, Huang X, Wang J, Yang L, Kong Y, Gao G, Zhang L, Chen ZS, Xie X(?).circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. Mol Cancer. 2019 Feb 11;18(1):23. doi: 10.1186/s12943-019-0946-x. （IF：7.776）
4.Xie X, Wang J, Shi D, Zou Y, Xiong Z, Li X, Zhou J, Tang H, Xie X(?).Identification of a 4-mRNA metastasis-related prognostic signature for patients with breast cancer. J Cell Mol Med. 2019 Feb;23(2):1439-1447. doi: 10.1111/jcmm.14049. Epub 2018 Nov 28 ( IF:4.302）
5.Chen B, Wei W, Huang X, Xie X, Kong Y, Dai D, Yang L, Wang J, Tang H(?), Xie X(?). circEPSTI1 as a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression.Theranostics. 2018 Jul 1;8(14):4003-4015. doi: 10.7150/thno.24106. eCollection 2018. （IF：8.537）
6.Chen B, Tang H, Chen X, Zhang G, Wang Y, Xie X, Liao N. Transcriptomic analyses identify key differentially expressed genes and clinical outcomes between triple-negative and non-triple-negative breast cancer. Cancer Manag Res. 2018 Dec 21;11:179-190. doi: 10.2147/CMAR.S187151.
7.Xie X, Tan W, Chen B, Huang X, Peng C, Yan S, Yang L, Song C, Wang J, Zheng W, Tang H(?), Xie X(?).Preoperative prediction nomogram based on primary tumor miRNAs signature and clinical-related features for axillary lymph node metastasis in early-stage invasive breast cancer. Int J Cancer. 2018 May 1;142(9):1901-1910. doi: 10.1002/ijc.31208. Epub 2018 Jan 12（IF：7.36）
8.Huang X, Xie X, Liu P, Yang L, Chen B, Song C, Tang H(?), Xie X(?).Adam12 and lnc015192 act as ceRNAs in breast cancer by regulating miR-34a. Oncogene. 2018 Jul 24. doi: 10.1038/s41388-018-0410-1. [Epub ahead of print] （IF：6.854）
9.Luo L, Tang H, Ling L, Li N, Jia X, Zhang Z, Wang X, Shi L, Yin J1, Qiu N, Liu H, Song Y, Luo K, Li H, He Z, Zheng G(?), Xie X(?). LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer. Oncogene. 2018 Jul 12. doi: 10.1038/s41388-018-0396-8. [Epub ahead of print] （IF：6.854）
10.Wu J, Shuang Z, Zhao J, Tang H, Liu P, Zhang L, Xie X(?), Xiao X(?). Linc00152 promotes tumorigenesis by regulating DNMTs in triple-negative breast cancer. Biomed Pharmacother. 2018 Jan;97:1275-1281. doi: 10.1016/j.biopha.2017.11.055. Epub 2017 Dec 14 （IF：3.457）
11.Kong Y, Lyu N, Wu J, Tang H, Xie X, Yang L, Li X, Wei W, Xie X(?). Breast cancer stem cell markers CD44 and ALDH1A1 in serum: distribution and prognostic value in patients with primary breast cancer. Journal of Cancer 2018, Vol. 9 018; 9(20): 3728-3735. doi: 10.7150/jca.28032 （IF：3.249）
12.Li X, Dai D, Chen B, Tang H, Xie X(?), Wei W(?). The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis. J Cancer. 2018 Feb 12;9(5):861-871. doi: 10.7150/jca.23367. eCollection 2018. （IF：3.249）
13.Xiao W, Zheng S, Liu P, Zou Y, Xie X, Yu P, Tang H(?), Xie X(?). Risk factors and survival outcomes in patients with breast cancer and lung metastasis: a population-based study. Cancer Med. 2018 Mar;7(3):922-930. doi: 10.1002/cam4.1370. Epub 2018 Feb 23. （IF：3.202）
14.Xiao W, Zheng S, Yang A, Zhang X, Liu P, Xie X, Tang H, Xie X(?). Incidence and Survival Outcomes of Breast Cancer with Synchronous Hepatic Metastases: A Population-Based Study. J Cancer. 2018 Oct 21;9(23):4306-4313. doi: 10.7150/jca.29190. eCollection 2018. （IF：3.249）
15.Xiao W, Zheng S, Yang A, Zhang X, Zou Y, Tang H, Xie X(?). Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study. Cancer Manag Res. 2018 Nov 5;10:5329-5338. doi: 10.2147/CMAR.S176763. eCollection 2018 （IF：3.702）
16.Li X, Dai D, Chen B, Tang H, Xie X(?), Wei W(?). Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients. Dis Markers. 2018 May 2;2018:**. doi: 10.1155/2018/**. eCollection 2018. Review.
（IF：2.949）
17.Xie X, Wang J, Shi D, Zou Y, Xiong Z, Li X, Zhou J, Tang H, Xie X. Identification of a 4-mRNA metastasis-related prognostic signature for patients with breast cancer. J Cell Mol Med. 2018 Nov 28. doi: 10.1111/jcmm.14049. [Epub ahead of print] （IF：4.302）
18.Li X, Dai D, Chen B, Tang H, Xie X(?), Wei W(?)..Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials. PLoS One. 2018 Feb 6;13(2):e**. doi: 10.1371/journal.pone.**. eCollection 2018. （IF：2.766）
19.Xie X, Huang X, Tang H, Ye F, Yang L, Guo X, Tian Z, Xie X, Peng C(?), Xie X(?). Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling.Curr Cancer Drug Targets. 2018;18(6):592-599. doi: 10.2174/**66**7. （IF：2.626）
20.Tang H, Peng F, Huang X, Xie X, Chen B, Shen J, Gao F, You J, Xie X(?), Chen J(?). Neoisoliquiritigenin Inhibits Tumor Progression by Targeting GRP78-β- catenin Signaling in Breast Cancer. Curr Cancer Drug Targets. 2018;18(4):390-399. doi: 10.2174/**66**5. （IF：2.626）
21.Wu J, Liu P, Tang H, Shuang Z, Qiu Q, Zhang L, Song C, Liu L, Xie X(?), Xiao X(?). FOXP2 Promotes Tumor Proliferation and Metastasis by Targeting GRP78 in Triple-negative Breast Cancer. Curr Cancer Drug Targets. 2018;18(4):382-389. （IF：2.626）
22.Li X, Dai D, Chen B, Tang H, Xie X(?), Wei W(?). Determination of the prognostic value of preoperative CA15-3 and CEA in predicting the prognosis of young patients with breast. Cancer. Oncol Lett. 2018 Oct;16(4):4679-4688. doi: 10.3892/ol.2018.9160. Epub 2018 Jul 17 . （IF：1.664）
23.Xiao W, Zou Y, Zheng S, Hu X, Liu P, Xie X, Yu P, Tang H, Xie X(?). Primary tumor resection in stage IV breast cancer: A systematic review and meta-analysis. Eur J Surg Oncol. 2018 Oct;44(10):1504-1512. doi: 10.1016/j.ejso.2018.08.002. Epub 2018 Aug . （IF：3.688）
24.Lin X, Chen W, Wei F, Zhou BP, Hung MC, Xie X(?).Nanoparticle Delivery of miR-34a Eradicates Long-term-cultured Breast Cancer Stem Cells via Targeting C22ORF28 Directly. Theranostics. 2017 Oct 17;7(19):4805-4824. doi: 10.7150/thno.20771. eCollection 2017.(IF 8.712)
25.Lin X, Chen W, Wei F, Zhou BP, Hung MC, Xie X(?). POMC maintains tumor-initiating properties of tumor tissue-derived long-term-cultured breast cancer stem cells. Int J Cancer. 2017 Jun 1;140(11):2517-2525. doi: 10.1002/ijc.30658. Epub 2017 Mar 16. (IF 6.513)
26.Wang J, Song C, Tang H, Zhang C, Tang J, Li X, Chen B, Xie X(?). miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. Breast Cancer Res. 2017 Jun 19;19(1):72. doi: 10.1186/s13058-017-0865-y. (IF 6.354)
27.Huang X, Xie X, Wang H, Xiao X, Yang L, Tian Z, Guo X, Zhang L, Tang H, Xie X(?).PDL1 And LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a.J Exp Clin Cancer Res. 2017 Sep 15;36(1):129. doi: 10.1186/s13046-017-0593-2. (IF 5.189)
28.Chen B, Wang J, Dai D, Zhou Q, Guo X, Tian Z, Huang X, Yang L, Tang H, Xie X(?).AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.J Exp Clin Cancer Res. 2017 May 12;36(1):65. doi: 10.1186/s13046-017-0522-4. (IF 5.189)
29.Wang N, Wang Q, Tang H, Zhang F, Zheng Y, Wang S, Zhang J, Wang Z(?), Xie X(?).Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells.J Exp Clin Cancer Res. 2017 Dec 2;36(1):172. doi: 10.1186/s13046-017-0635-9. (IF 5.189)
30.He X, Ye F, Zhao B, Tang H, Wang J, Xiao X, Xie X(?).Risk factors for delay of adjuvant chemotherapy in non-metastatic breast cancer patients: A systematic review and meta-analysis involving 186982 patients. PLoS One. 2017 Mar 16;12(3):e**. doi: 10.1371/journal.pone.**. (IF 3.362)
31.He X, Ye F, Li M, Yu P, Xiao X, Tang H, Xie X(?).Application of a novel prognostic invasive lesion index in ductal carcinoma in situ with minimal invasion of the breast.Cancer Med. 2017 Nov;6(11):2489-2496. doi: 10.1002. (IF 2.916)
32.He XF, Ye F, Wen JH, Li SJ, Huang XJ, Xiao XS, Xie XM.High Residual Tumor Rate for Early Breast Cancer Patients Receiving Vacuum-assisted Breast Biopsy.J Cancer. 2017 Feb 11;8(3):490-496. doi: 10.7150/jca.17305. eCollection 2017. (IF 2.916)
33.Wen J, Yang Y, Liu P, Ye F, Tang H, Huang X, Zhong S, Xie X(?).Development and validation of a nomogram for predicting survival on the base of modified lymph node ratio in breast cancer patients. Breast. 2017 Jun;33:14-22. doi: 10.1016. (IF 2.801)
34.Li X, Tang H, Wang J, Xie X, Liu P, Kong Y, Ye F, Shuang Z, Xie Z, Xie X(?). The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer. Breast. Breast. 2017 Apr;32:1-6. doi: 10.1016. (IF 2.801)
35.Lin X, Li J, Ying M, Wei F, Xie X(?). Diabetes Increases Morbidities of Colonic Diverticular Disease and Colonic Diverticular Hemorrhage: A Systematic Review and Meta-Analysis. Am J Ther. 2017 Mar/Apr;24(2):e213-e221. doi: 10.1097. (IF 1.588)
36.Liu P, Ye F, Xie X, Li X, Tang H, Li S, Huang X, Song C, Wei W (?),Xie X(?). mir-101-3p is a key regulator of tumor metabolism in triple negative breast cancer targeting AMPK. Oncotarget. 2016 Apr 28. 7(23): 35188-98.(IF 5.168)
37.Wen J, Ye F, He X, Li S, Huang X, Xiao X, Xie X(?). Development and validation of a prognostic nomogram based on the log odds of positive lymph nodes (LODDS) for breast cancer. Oncotarget. 2016 Apr 12;7(15):21046-53. (IF 5.168)
38.Tan W, Xie X, Li L, Tang H, Ye X, Chen L, Tang W, Gao J, Pan L, Zhang X, Ye F, Li X, Yang L, Xie X(?), Zheng W(?). Diagnostic and prognostic value of serum MACC1 in breast cancer patients. Oncotarget. 2016 Oct 25. doi: 10.18632. (IF 5.168)
39.Xiao X, Huang X, Ye F, Chen B, Song C, Wen J, Zhang Z, Zheng G, Tang H (?),Xie X(?). The miR-34a-LDHA axis regulates glucose metabolism and tumor growth in breast cancer Sci Rep. 2016 Feb 23;6:21735. (IF 4.259)
40.Song C, Zhang L, Wang J, Huang Z, Li X, Wu M, Li S, Tang H (?), Xie X(?). High expression of microRNA-183/182/96 cluster as a prognostic biomarker for breast cancer.Sci Rep. 2016 Apr 13;6:24502. (IF 4.259)
41.Chen B , Dai D, Tang H, Chen X, Ai X, Huang X, Wei W (?),Xie X(?). Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer. J. Cancer 2016; 7(15): 2309-2316. (IF 2.916)
42.Dai D, Chen B, Wang B, Tang H, Li X, Zhao Z, Li X, Xie X(?), Wei W. Pretreatment TG/HDL-C Ratio Is Superior to Triacylglycerol Level as an Independent Prognostic Factor for the Survival of Triple Negative Breast Cancer Patients. J Cancer. 2016 Aug 7;7(12):1747-1754. (IF 2.916)
43.Chen B, Dai D, Tang H, Ai X, Chen X, Zhang X, Li Z, Xie X(?). Pretreatment Hematocrit Is Superior to Hemoglobin as a Prognostic Factor for Triple Negative Breast Cancer. PLoS One. 2016 Nov 16;11(11):e**. (IF 2.806)
44.Dai D, Chen B , Tang H, Wang B, Zhao Z, Xie X(?), Wei W (?).Nomograms for Predicting the Prognostic Value of Pre-Therapeutic CA15-3 and CEA Serum Levels in TNBC Patients.PLoS One. 2016 Aug 25;11(8):e**. (IF 2.806)
45.Huang X, Li X, Xie X, Ye F, Chen B, Song C, Tang H (?), Xie X(?). High expressions of LDHA and AMPK as prognostic biomarkers for breast cancer. Breast. 2016 Sep 3;30:39-46. (IF 2.801)
46.Xie X, Tang H, Liu P, Kong Y, Wu M, Xiao X, Yang L, Gao J, Wei W, Lee J, Bartholomeusz C, Ueno NT(?), Xie X(?). Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. Cancer Lett. 2015 Jan 28; 356(2 Pt B):374-81. (IF: 6.375)
47.Chen B, Tang H, Liu X, Liu P, Yang L, Xie X, Ye F, Song C, Xie X(?), Wei W(?). miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer. Cancer Lett. 2015 Jan 28;356(2 Pt B):410-7. (IF: 6.375)
48.Liu P, Tang H, Chen B, He Z, Deng M, Wu M, Liu X, Yang L, Ye F, Xie X(?). miR-26a suppresses tumour proliferation and metastasis by targeting metadherin in triple negative breast cancer. Cancer Lett. 2015 Feb 1;357(1):384-92. (IF: 6.375)
49.Yang L, Tang H, Kong Y, Xie X, Chen J, Song C, Liu X, Ye F, Li N, Wang N, Xie X(?). LGR5 Promotes Breast Cancer Progression and Maintains Stem-Like Cells Through Activation of Wnt/β-Catenin Signaling.Stem Cells. 2015 Oct;33(10):2913-24. (IF: 5.599)
50.Song C, Liu L, Pei X, Liu X, Yang L, Ye F, Xie X, Chen J, Tang H (*), Xie X(?). miR-200c inhibits breast cancer proliferation by targeting KRAS. Oncotarget. 2015 Oct 27; 6(33):34968-78. (IF: 5.168)
51.Liu X, Tang H, Chen J, Song C, Yang l, Wang N, XieX, Lin X, Xie X(?). MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer. Oncotarget. 2015 Aug 21;6(24):20070-83. (IF: 5.168)
52.Wang J, Zhang C, Chen K, Tang H, Tang J, Song C, Xie X(?). ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer. Breast Cancer Res Treat. 2015 Jul;152(2):255-69. (IF:3.626)
53.Lin X, Chen W, Wei F, Ying M, Wei W, Xie X(?). Night-shift work increases morbidity of breast cancer and all-cause mortality: a meta-analysis of 16 prospective cohort studies. Sleep Med. 2015 Nov;16(11):1381-7. (IF:3.391)
54.Wen J, Ye F, Li S, Huang X, Yang L, Xiao X, Xie X(?).The Practicability of a Novel Prognostic Index (PI) Model and Comparison with Nottingham Prognostic Index (NPI) in Stage I-III Breast Cancer Patients Undergoing Surgical Treatment.PLoS One. 2015 Nov 23;10(11):e**. (IF: 2.806)
55.Wen J, Yang Y, Ye F, Huang X, Li S, Wang Q, Xie X(?). The preoperative plasma fibrinogen level is an independent prognostic factor for overall survival of breast cancer patients who underwent surgical treatment. Breast. 2015 Dec;24(6):745-50. (IF: 2.801)
56.Jiao S, Liu W, Wu M, Peng C, Tang H, Xie X(?). Nrdp1 expression to predict clinical outcome and efficacy of adjuvant anthracyclines-based chemotherapy in breast cancer: ewline A retrospective study. Cancer Biomark. 2015 Jan 1;15(2):115-23. (IF:2.274)
57.Lin X, Li J, Chen W, Wei F, Ying M, Wei W, Xie X(?). Diabetes and risk of anastomotic leakage after gastrointestinal surgery. J Surg Res. 2015 Jun 15;196(2):294-301. (IF:2.187)
58.Wen J, Ye F, Huang X, Li S, Yang L, Xiao X, Xie X(?). Prognostic Significance of Preoperative Circulating Monocyte Count in Patients With Breast Cancer: Based on a Large Cohort Study. Medicine (Baltimore). 2015 Dec;94(49):e2266. (IF: 1.803)
59.Tang H, Liu P, Yang L, Xie X, Ye F, Wu M, Liu X, Chen B, Zhang L, Xie X(?).miR-185 suppresses tumor proliferation by directly targeting E2F6 and DNMT1 and indirectly upregulating BRCA1 in triple-negative breast cancer. Mol Cancer Ther. 2014 Dec;13(12):3185-97. (IF: 6.107)
60.Xie X(?), Kong Y, Tang H, Yang L, Hsu JL, Hung MC. Targeted BikDD Expression Kills Androgen-Dependent and Castration-Resistant Prostate Cancer Cells. Mol Cancer Ther. 2014 Jul;13(7):1813-25. (IF: 6.107)
61.Ye F, Tang H, Liu Q, Xie X, Wu M, Liu X, Chen B, Xie X. (?) miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family. J Transl Med. 2014 Jan 21;12:17. doi: 10.1186/1479-5876-12-17.
62.Tang H, Xie X , Guo J, Wei W, Wu M, Liu P, Kong Y, Yang L, Hung MC, Xie X(?). Efficient systemic DNA delivery to the tumor by self-assembled nanoparticle. J Nanopart Res. 2014.16.2213.
63.Xiao X, Chen B, Liu X, Liu P, Zheng G, Ye F, Tang H, Xie X(?). Diallyl disulfide suppresses SRC/Ras/ERK signaling-mediated proliferation and metastasis in human breast cancer by up-regulating miR-34a. PLoS One. 2014 Nov 14;9(11):e112720. (IF: 3.234)
64.Jiao S, Wu M, Ye F, Tang H, Xie X, Xie X(?). BikDDA, a Mutant of Bik with Longer Half-Life Expression Protein, Can Be a Novel Therapeutic Gene for Triple-Negative Breast Cancer. PLoS One. 2014 Mar 17;9(3):e92172.
65.Lin X, Wu M, Liu P, Wei F, Li L, Tang H, Xie X, Liu X, Yang L, Xie X(?). Up-regulation and worse prognostic marker of cytoplasmic TARBP2 expression in obstinate breast cancer. Med Oncol. 2014 Apr;31(4):868. doi: 10.1007/s12032-014-0868-9. Epub 2014 Feb 22.
66.Wang J, Zhang X, He J, Yang M, Tang J, Li X, Tang H, Xie X(?). Co-expression of EGFR and CK5/6 in primary squamous cell carcinoma of the breast. Med Oncol. 2014 Sep;31(9):172. doi: 10.1007/s12032-014-0172-8. (IF: 2.058)
67.Wang K, Ren Y, Huang R, He J, Feng W, Kong Y, Xu F, Zhao L, Song Q, Li J, Zhang B, Fan J, Xie X(?), Zheng S, Qiao YL. Application of intraoperative frozen section examination in the management of female breast cancer in China: a nationwide, multicenter 10-year epidemiological study. World J Surg Oncol. 2014 Jul 18;12:225. doi: 10.1186/1477-7819-12-225.
68.Yang L, Li N, Wang S, Kong Y, Tang H, Xie X, Xie X(?). Lack of Association Between the Matrix Metalloproteinase-2 -1306C>T Polymorphism and Breast Cancer Susceptibility: a Meta-analysis.Asian. Pac J Cancer Prev. 2014;15(12):4823-7.
69.Tang H, Deng M, Tang Y, Xie X, Guo J, Kong Y, Ye F, Su Q and Xie X(?).miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression. Clinical Cancer Research 2013 Oct 15;19(20):5602-12. (IF: 7.837)
70.Tang H, Kong Y, Guo J, Tang Y, Xie X, Yang L, Su Q, Xie X(?). Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22. Cancer Lett. Cancer Lett. 2013 Oct 28;340(1):72-81 (IF:4.258)
71.Li L, Yuan L, Luo J, Gao J, Guo J, Xie X(?). MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin Exp Med. 2013 May;13(2):109-17.(IF:2.397)
72.Kong Y, Wang J, Liu W, Chen Q, Yang J, Wei W, Wu M, Yang L, Xie X, Lv N, Guo J, Li L, Gao J, Xie X(?), Dai S(?). Cytokeratin19-2g2, a novel fragment of cytokeratin19 in serum, indicating a more invasive behavior and worse prognosis in breast cancer patients. PLoS One. 2013;8(2):e57092. (IF:3.73)
73.Kong Y, Yang L, Tang H, Lv N, Xie X, Li J, Guo J, Li L, Wu M, Gao J, Yang H, Tang Z, He J, Zhang B, Li H, Qiao Y, Xie X?).A nation-wide multicenter retrospective study of the epidemiological, pathological and clinical characteristics of breast cancer in situ in chinese women in 1999 - 2008. PLoS One. 2013;8(2):e57092.. (IF:3.73)
74.Gao J, Li L, Wu M, Liu M, Xie X, Guo J, Tang H, Xie X(?). MiR-26a Inhibits Proliferation and Migration of Breast Cancer through Repression of MCL-1. PLoS One. 2013 Jun 4;8(6):e65138. (IF:3.73)
75.Guo J, Li W, Shi H, Xie X, Li L, Tang H, Wu M, Kong Y, Yang L, Gao J, Liu P, Wei W, Xie X(?). Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a. Mol Cell Biochem. 2013 Oct;382(1-2):103-11. (IF:2.392)
76.Wang J, Xie X(?), Wang X, Tang J, Pan Q, Zhang Y, Di M. Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: A meta-analysis. Surg Oncol. 2013；222(4):247-55 (IF:2.136)
77.Li X, Feng YF, Wei WD, Liu P, Xie ZM, Wang J, Xie X(?). Signet-ring cell carcinoma of the breast: a case report. World J. of Surgical oncology. 2013;11:183-186. (IF: 1.092)
78.Wu MQ, Hu P, Gao J, Wei WD, Xiao XS, Tang HL, Li X, Ge QD, Jia WH, Liu RB, Xie X (?).Low expression of tyrosine-protein phosphatase nonreceptor type 12 is associated with lymph node metastasis and poor prognosis in operable triple-negative breast cancer. Asian Pac J Cancer Prev. 2013;14(1):287-92. (IF:1.271)
79.Xiao X, Tang H, Xie X, Li L, Kong Y, Wu M, Yang L, Gao J, Wei W and Xie X(?).Metastatic axillary lymph node ratio(LNR) is prognostically superior to pN staging in patients with breast cancer -- results from a single institution study of 804 Chinese patients. Asian Pac J Cancer Prev. 2013;14(1):287-92. (IF:1.271)
80.Li L, Xie X, Luo J, Wei W , Xi S, Guo J, Kong Y, Wu M, Gao J, Xie Z, Tang J, Wang X, Yang M, Hung MC, X Xie (?). Targeted Expression of miR-34a by T-VISA System Suppresses Tumor Cell Growth and Invasion in Breast Cancer. Mol Therapy; 2012; 20(12):2326-2334 (IF:6.873)
81.Xie X, L Li, X Xiao, J Guo, Y Kong, M Wu, W Liu, G Gao, J L. Hsu, W Wei, M-C Hung (?) and X Xie(?). Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models. Mol Cancer Ther.2012 ;11(9);1915-1924. (IF:5.226)
82.Wu M, Wei W, Xiao X, Guo J, Xie X, Li L, Kong Y, Lv N, Jia W, Zhang Y, Xie X(?). Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med Oncol. 2012 ; 3240-3249 (IF:2.14)
83.Su Y, Tang LY, Chen LJ, He JR, Su FX, Lin Y, Chen WQ, Xie X(?), Ren ZF(?). Joint Effects of Febrile Acute Infection and an Interferon-γ Polymorphism on Breast Cancer Risk. PLoS One. 2012;7(5):e37275. (IF:4.092)
84.Kong Y, Dai S, Xie X, Xiao X, Lv N, Guo J, Li L, Jia W, Zhang Y, Liu W, Wei W, Xie X(?). High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. J Cancer Res Clin Oncol. 2012; 2012;138(2):275-84. (IF:2.558)
85.Lv N, Lin S, Xie Z, Tang J, Ge Q, Wu M, Xie X, Xie X(?), Wei W(?). Absence of evidence for epidermal growth factor receptor and human homolog of the Kirsten rat sarcoma-2 virus oncogene mutations in breast cancer. Cancer Epidemiol. 2012;36(4);341-346. (IF:2.010)
86.Li L, Xie X, Luo J, Wei W , Xi S, Guo J, Kong Y, Wu M, Gao J, Xie Z, Tang J, Wang X, Yang M, Hung MC, Xie X, Guo J, Kong Y, Xie GX, Li L, Lv N, Xiao X, Tang J, Wang X, Liu P, Yang M, Xie Z, Wei W, Xie X(?).Targeted expression of E. coli purine nucleoside phosphorylase and Fludara for prostate cancer therapy. J Gene Med. 2011;13:680-691. (IF:3.079)
87.A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Therapeutics. 2009; 8(8):2375-82. (IF: 5.225).
88.Xie, X(?)., Xia, W., Li, Z., Kuo, H-P.,Liu, Y., Li, Z., Ding, Q., Zhang, S., Spohn, W., Yang, Y., Wei, Y., Lang, J-Y., Evans, D.B., Chiao, P.J., Abbruzzese J.L. and Hung, M-C. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell, 2007;12(July10):52-65. (IF: 26.925).
89.Xie, X(?), Z Luo, KM Slawin, and DM Spencer. The EZC-Prostate Model: Non-invasive prostate imaging in living mice. Mol Endocrinol 2004;18(3):722-732. (IF:5.389).
90.Xie X(?), X Zhou, Y Liu, K Slawin, and D Spencer. Adenovirus-mediated tissue-targeted expression of a caspase 9-based artificial death switch for the treatment of prostate cancer. Cancer Res 2001; 61: 6795-804. (IF: 8.234).
91.Xie X(?), X Zhao, Y Liu, CYF Young, DJ Tindall, K Slawin, and D Spencer. Robust prostate-specific expression for targeted gene therapy based on human kallikrein 2 (hK2) promoter. Human Gene Therapy 2001;12(5): 549-61. (IF: 4.829).
92.Xie X(?), CE Forsmark, and JY Lau. Effect of bile and pancreatic juice on adenovirus-mediated gene delivery: Implications on the feasibility of gene delivery through ERCP. Digestive Diseases and Sciences 2000; 45(2):230-36. (IF:1.583).

（共同作者63篇，影响因子350）：
93.He R, Liu P, Xie X, Zhou Y, Liao Q, Xiong W, Li X, Li G, Zeng Z, Tang H.circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a.J Exp Clin Cancer Res. 2017 Oct 16;36(1):145. doi: 10.1186/s13046-017-0614-1.
94.Zhang W, Wang MY, Wei XL, Lin Y, Su FX, Xie XM, Tang LY, Ren ZF. Associations of Epstein-Barr Virus DNA in PBMCs and the Subtypes with Breast Cancer Risk.J Cancer. 2017 Aug 25;8(15):2944-2949. doi: 10.7150/jca.20330. eCollection 2017.
95.Xie ZM, Sun J, Hu ZY, Wu YP, Liu P, Tang J, Xiao XS, Wei WD, Wang X, Xie XM, Yang MT.Survival outcomes of patients with lobular carcinoma in situ who underwent bilateral mastectomy or partial mastectomy.Eur J Cancer. 2017 Sep;82:6-15. doi: 10.1016/j.ejca.2017.05.030. Epub 2017 Jun 21.
96.Zhu RM, Lin W, Zhang W, Ren JT, Su Y, He JR, Lin Y, Su FX, Xie XM, Tang LY, Ren ZF.Modification effects of genetic polymorphisms in FTO, IL-6, and HSPD1 on the associations of diabetes with breast cancer risk and survival.PLoS One. 2017 Jun 7;12(6):e**. doi: 10.1371/journal.pone.**. eCollection 2017.
97.Liu Y, Zhang J, Huang R, Feng WL, Kong YN, Xu F, Zhao L, Song QK, Li J, Zhang BN, Fan JH, Qiao YL, Xie XM, Zheng S, He JJ, Wang K.Influence of occupation and education level on breast cancer stage at diagnosis, and treatment options in China: A nationwide, multicenter 10-year epidemiological study.Medicine (Baltimore). 2017 Apr;96(15):e6641. doi: 10.1097/MD.6641
98.Zhang J, Li X, Huang R, Feng WL, Kong YN, Xu F, Zhao L, Song QK, Li J, Zhang BN, Fan JH, Qiao YL, Xie XM, Zheng S, He JJ, Wang K.A nomogram to predict the probability of axillary lymph node metastasis in female patients with breast cancer in China: A nationwide, multicenter, 10-year epidemiological study.Oncotarget. 2017 May 23;8(21):35311-35325. doi: 10.18632/oncotarget.13330.
99.Li Q, Yang Z, Fan J, He J, Zhang B, Yang H, Xie X, Tang Z, Li H, Qiao Y, Zhang P.A nation-wide multicenter 10-year (1999-2008) retrospective study of chemotherapy in Chinese breast cancer patients.Oncotarget. 2017 Mar 22;8(44):75864-75873. doi: 10.18632/oncotarget.16439. eCollection 2017 Sep 29.
100.Gao F, Zhang J, Fu C, Xie X, Peng F, You J, Tang H, Wang Z, Li P, Chen J. iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability.Int J Nanomedicine. 2017 Jun 1;12:4147-4162. doi: 10.2147/IJN.S134148. eCollection 2017
101.Zhang J, Li X, Huang R, Feng WL, Kong YN, Xu F6, Zhao L, Song QK2, Li J, Zhang BN, Fan JH, Qiao YL, Xie XM, Zheng S, He JJ, Wang K. A nomogram to predict the probability of axillary lymph node metastasis in female patients with breast cancer in China: A nationwide, multicenter, 10-year epidemiological study. Oncotarget. 2016 Nov 12. doi: 10.18632/oncotarget.13330. [Epub ahead of print]
102.Zhang W, Zhang ZZ, Tang LY, Lin Y, Su FX, Xie XM, Su XF, Ren ZF. Genetic variants in EBV reactivation-related genes and the risk and survival of breast cancer. Tumour Biol. 2016 Jun;37(6):8337-47. doi: 10.1007/s13277-015-4562-0.
103.Zhang BL, Sivasubramaniam PG, Zhang Q, Wang J, Zhang B, Gao JD, Tang ZH, Chen GJ, Xie XM, Wang Z, Yang HJ, He JJ, Li H, Li JY, Fan JH, Wang X, Qiao YL. Trends in Radical Surgical Treatment Methods for Breast Malignancies in China: A Multicenter 10-Year Retrospective Study. Oncologist. 2015 Sep;20(9):1036-43.
104.Zhang B, Song Q, Zhang B, Tang Z, Xie X, Yang H, He J, Li H, Li J, Li J, Fan J, Huang R, Zhang H, Qiao Y. A 10-year (1999 ～ 2008) retrospective multi-center study of breast cancer surgical management in various geographic areas of China. Oncologist. 2015 Sep;20(9):1044-50. doi: 10.1634/theoncologist.2014-0290.
105.Tang H, Liu Q, Liu X, Ye F, Xie X, Xie X, Wu M. Plasma miR-185 as a predictive biomarker for prognosis of malignant glioma.J Cancer Res Ther. 2015 Jul-Sep;11(3):630-4.
106.Wang Z, Wang N, Liu P, Peng F, Tang H, Chen Q, Xu R, Dai Y, Lin Y, Xie X, Peng C, Situ H.Caveolin-1, a stress-related oncotarget, in drug resistance. Oncotarget. 2015 Sep 27. [Epub ahead of print.
107.Sivasubramaniam PG, Zhang BL, Zhang Q, Smith JS, Zhang B, Tang ZH, Chen GJ, Xie XM, Xu XZ, Yang HJ, He JJ, Li H, Li JY, Fan JH, Qiao YL. Breast Cancer Disparities: A Multicenter Comparison of Tumor Diagnosis, Characteristics, and Surgical Treatment in China and the U.S. Oncologist. Oncologist. 2015 Sep;20(9):1044-50.
108.Wang N, Wang Z, Wang Y, Xie X, Shen J, Peng C, You J, Peng F, Tang H, Guan X, Chen J . Dietary compound isoliquiritigenin prevents mammary carcinogenesis by inhibiting breast .cancer stem cells through WIF1 demethylation. Oncotarget. 2015 Apr 30;6(12):9854-76.
109.Zhang Y, Chen Y, Chen D, Jiang Y, Huang W, Ouyang H, Xing W, Zeng M, Xie X, Zeng W.Impact of preoperative anemia on relapse and survival in breast cancer patients.BMC Cancer. 2014 Nov 18;14:844. doi: 10.1186/1471-2407-14-844.
110.Song QK, Li J, Huang R, Fan JH, Zheng RS, Zhang BN, Zhang B, Tang ZH, Xie XM, Yang HJ, He JJ, Li H, Li JY, Qiao YL, Chen WQ. Age of diagnosis of breast cancer in china: almost 10 years earlier than in the United States and the European union. Asian Pac J Cancer Prev. 2014;15(22):10021-5.
111.Zhou C, He Jj, Li J, Fan Jh, Zhang B, Yang Hj, Xie Xm, Tang Zh, Li H, Li Jy, Wang Sl, Qiao Yl, Huang R, Zhang P. A nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer. PLoS One. 2014 Jul 18;9(7):e100159. doi: 10.1371/journal.pone.**. eCollection 2014.
112.Xie Z, Wang X, Lin H, Wei W, Liu P, Xiao X, Xie X, Guan X, Yang M, Tang J. Breast-conserving therapy: a viable option for young women with early breast cancer--evidence from a prospective study. Ann Surg Oncol. 2014 Jul;21(7):2188-96. doi: 10.1245/s10434-014-3620-y. Epub 2014 Mar 6.
113.Li J, Huang Y, Zhang BN, Fan JH, Huang R, Zhang P, Wang SL, Zheng S, Zhang B, Yang HJ, Xie XM, Tang ZH, Li H, He JJ, Hsieh E, Qiao YL, Li JY. Body mass index and breast cancer defined by biological receptor status in pre-menopausal and post-menopausal women: a multicenter study in China. PLoS One. 2014 Jan 29;9(1):e87224.
114.Lee H, Li JY, Fan JH, Li J, Huang R, Zhang BN, Zhang B, Yang HJ, Xie XM, Tang ZH, Li H, He JJ, Wang Q, Huang Y, Qiao YL, Pang Y. Risk factors for breast cancer among Chinese women: a 10-year nationwide multicenter cross-sectional study. J Epidemiol. 2014;24(1):67-76. Epub 2013 Nov 23.
115.Song Q, Huang R, Li J, Fan J, Zheng S, Zhang B, Yang H, Tang Z, He J, Xie X, Li H, Li J, Qiao Y. The Diverse Distribution of Risk Factors between Breast Cancer Subtypes of ER, PR and HER2: A 10-Year Retrospective Multi-Center Study in China. PLoS One. 2013 Aug 20;8(8):e72175. doi: 10.1371/journal.pone.**.
116.Li L, Luo J, Wang B, Wang D, Xie X, Yuan L, Guo J, Xi S, Gao J, Lin X, Kong Y, Xu X, Tang H, Xie X, Liu M.Microrna-124 targets flotillin-1 to regulate proliferation and migration in breast cancer. Mol Cancer. 2013 Dec 13;12:163. doi: 10.1186/1476-4598-12-163.
117.Song Q, Huang R, Li J, Fan J, Zheng S, Zhang B, Yang H, Tang Z, He J, Xie X, Li H, Li J, Qiao Y.The diverse distribution of risk factors between breast cancer subtypes of ER, PR and HER2: a 10-year retrospective multi-center study in China. PLoS One. 2013 Aug 20;8(8):e72175. doi: 10.1371/journal.pone.007217
118.Wang SL, Li YX, Zhang BN, Li J, Fan JH, He JJ, Song QK, Zhang P, Zheng S, Zhang B, Yang HJ, Xie XM, Tang ZH, Li H, Li JY, Qiao YL. Epidemiologic study of radiotherapy use in China in patients with breast cancer between 1999 and 2008. Clin Breast Cancer. 2013 Feb;13(1):47-52. doi: 10.1016/j.clbc.2012.09.012. Epub 2012 Oct 25.
119.Wang SL, Li YX, Zhang BN, Li J, Fan JH, Pang Y, Zhang P, Zheng S, Zhang B, Yang HJ, Xie XM, Tang ZH, Li H, Li JY, He JJ, Qiao YL. Epidemiologic study of compliance to postmastectomy radiation therapy guidelines in breast cancer patients in China between 1999 and 2008. Pract Radiat Oncol. 2013 Jul-Sep;3(3):209-15.
120.Zhang B, Song Q, Zhang B, Tang Z, Xie X, Yang H, He J, Li H, Li J, Li J, Fan J, Huang R, Zhang H, Qiao Y A 10-year (1999 ~ 2008) retrospective multi-center study of breast cancer surgical management in various geographic areas of China.Breast. 2013 Oct;22(5):676-81. doi: 10.1016/j.breast.2013.01.004.
121.Cen YL, Qi ML, Li HG, Su Y, Chen LJ, Lin Y, Chen WQ, Xie XM, Tang LY, Ren ZF. Associations of polymorphisms in the genes of FGFR2, FGF1, and RBFOX2 with breast cancer risk by estrogen/progesterone receptor status. Mol Carcinog. Mol Carcinog. 2013 Nov;52 Suppl 1:E52-9. doi: 10.1002/mc.21979.
122.Zhang BN, Zhang B, Tang ZH, Xie XM, Yang HJ, He JJ, Li H, Li JY, Li J, Fan JH, Huang R, Song QK, Zhang HM, Qiao YL.10-year changes and development of surgical treatment for breast cancer in China. Zhonghua Zhong Liu Za Zhi. 2012 Aug;34(8):582-7. doi: 10.3760/cma.j.issn.0253-3766.2012.08.005. Chinese.
123.Ge QD, Lv N, Kong YN, Xie XH, He N, Xie XM, Wei WD. Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases. Asian Pac J Cancer Prev. 2012;13(10):5081-6.
124.Su Y, Tang LY, Chen LJ, He JR, Su FX, Lin Y, Chen WQ, Xie XM, Ren ZF.Joint effects of febrile acute infection and an interferon-γ polymorphism on breast cancer risk. PLoS One. 2012;7(5):e37275. doi: 10.1371/journal.pone.**. Epub 2012 May 18.
125.Ge QD, Lv N, Cao Y, Wang X, Tang J, Xie ZM, Xiao XS, Liu P, Xie XM, Wei WD. A case report of primary small cell carcinoma of the breast and review of the literature. Chin J Cancer. 2012 Jul;31(7):354-8. doi: 10.5732/cjc.012.10012. Review.
126.Ma X, Beeghly-Fadiel A, Lu W, Shi J, Xiang YB, Cai Q, Shen H, Shen CY, Ren Z, Matsuo K, Khoo US, Iwasaki M, Long J, Zhang B, Ji BT, Zheng Y, Wang W, Hu Z, Liu Y, Wu PE, Shieh YL, Wang S, Xie X, Ito H, Kasuga Y, Chan KY, Iwata H, Tsugane S, Gao YT, Shu XO, Moses HL, Zheng W. Pathway Analyses Identify TGFBR2 as Potential Breast Cancer Susceptibility Gene: Results from a Consortium Study among Asians. Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1176-84. doi: 10.1158/1055-9965.EPI-12-0118. (IF:4.123)
127.Wang Q, Li J, Zheng S, Li JY, Pang Y, Huang R, Zhang BN, Zhang B, Yang HJ, Xie X, Tang ZH, Li H, He JJ, Fan JH, Qiao YL. Breast cancer stage at diagnosis and area-based socioeconomic status: a multicenter 10-year retrospective clinical epidemiological study in China. BMC Cancer. 2012 Mar 29;12:122. (IF:3.153)
128.Long J, Cai Q, Sung H, Shi J, Zhang B, Choi JY, Wen W, Delahanty RJ, Lu W, Gao YT, Shen H, Park SK, Chen K, Shen CY, Ren Z, Haiman CA, Matsuo K, Kim MK, Khoo US, Iwasaki M, Zheng Y, Xiang YB, Gu K, Rothman N, Wang W, Hu Z, Liu Y, Yoo KY, Noh DY, Han BG, Lee MH, Zheng H, Zhang L, Wu PE, Shieh YL, Chan SY, Wang S, Xie X, Kim SW, Henderson BE, Le Marchand L, Ito H, Kasuga Y, Ahn SH, Kang HS, Chan KY, Iwata H, Tsugane S, Li C, Shu XO, Kang DH, Zheng W. Genome-wide association study in east Asians identifies novel susceptibility loci for breast cancer. PLoS Genet. 2012 Feb;8(2):e**. Epub 2012 Feb 23. (IF :9.543 )
129.Shao YZ, Liu LZ, Bie MJ, Li CC, Wu YP, Xie X, Li L. Characterizing the clustered microcalcifications on mammograms to predict the pathological classification and grading: a mathematical modeling approach. J Digit Imaging. 2011 Oct;24(5):764-71. (IF:1.413 )
130.Lv N, Xie X, Ge Q, Lin S, Wang X, Kong Y, Shi H, Xie X, Wei W. Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations. Diagn Pathol. 2011 Dec 2;6(1):118. (IF: 1.388)
131.Liu Y, Lang F, Xie X, Prabhu S, Xu J, Sampath D, Aldape K, Fuller G, Puduvalli VK. Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts. Cell Death Dis. 2011 Feb 24;2:e121.（IF：5.333）
132.Li J, Zhang BN, Fan JH, Pang Y, Zhang P, Wang SL, Zheng S, Zhang B, Yang HJ, Xie X, Tang ZH, Li H, Li JY, He JJ, Qiao YL. A Nation-Wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in china. BMC Cancer. 2011 Aug 22;11:364. (IF:3.153)
133.Xie ZM, Li LS, Laquet C, Penault-Llorca F, Uhrhammer N, Xie X, Bignon YJ. Germline mutations of the E-cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer. Cancer. 2011; 117 (14): 3112-17.(IF: 5.131)
134.Xiao X, Shi D, Liu L, Wang J, Xie X, Kang T, Deng W. Quercetin suppresses cyclooxygenase-2 expression and angiogenesis through inactivation of P300 signaling. PLoS One. 2011;6(8):e22934. Epub 2011 Aug 8. (IF: 4.411)
135.Lang JY, Hsu JL, Meric-Bernstam F, Chang CJ, Wang Q, Bao Y, Yamaguchi H, Xie X, Woodward WA, Yu D, Hortobagyi GN, Hung MC. BikDD Eliminates Breast Cancer Initiating Cells and Synergizes with Lapatinib for Breast Cancer Treatment. Cancer Cell. 2011 Sep 13;20(3):341-56.( IF: 26.925)
136.Cai Q, Long J, Lu W, Qu S, Wen W, Kang D, Lee JY, Chen K, Shen H, Shen CY, Sung H, Matsuo K, Haiman CA, Khoo US, Ren Z, Iwasaki M, Gu K, Xiang YB, Choi JY, Park SK, Zhang L, Hu Z, Wu PE, Noh DY, Tajima K, Henderson BE, Chan KY, Su F, Kasuga Y, Wang W, Cheng JR, Yoo KY, Lee JY, Zheng H, Liu Y, Shieh YL, Kim SW, Lee JW, Iwata H, Le Marchand L, Chan SY, Xie X, Tsugane S, Lee MH, Wang S, Li G, Levy S, Huang B, Shi J, Delahanty R, Zheng Y, Li C, Gao YT, Shu XO, Zheng W.Genome-wideassociation study identifies breast cancer risk variant at 10q21.2: results from the Asia Breast Cancer Consortium. Hum Mol Genet. 2011 Dec 15;20(24):4991-9. (IF : 8.058)
137.Ding Q, Chang CJ, Xie X, Xia W, Yang JY, Wang SC, Wang Y, Xia J, Chen L, Cai C, Li H, Yen CJ, Kuo HP, Lee DF, Lang J, Huo L, Cheng X, Chen YJ, Li CW, Jeng LB, Hsu JL, Li LY, Tan A, Curley SA, Ellis LM, Dubois RN, Hung M.APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. J Clin Invest. 2011 Nov 1;121(11):4526-36. (IF : 14.152)
138.Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu JM, Hortobagyi GN, Hung MC. EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-β Catenin Signaling. Cancer Cell. 2011;19:86-100 ( IF: 26.925)
139.Song H, Li CW, Labaff AM, Lim SO, Li LY, Kan SF, Chen Y, Zhang K, Lang J, Xie X, Wang Y, Huo LF, Hsu SC, Chen X, Zhao Y, Hung MC. Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors. Biochem Biophys Res Commun. 2011 Jan 7;404(1):68-73. (IF:2.595)
140.Tang J, X Xie, X Wang, Z Xie, J He, Y Wu, W Fan, J Fu and M Yang. Radiocolloid in combination with methylene dye localization, rather than wire localization, is a preferred procedure for excisional biopsy of nonpalpable breast lesions. Ann Surg Oncol. 2011 Jan;18(1):109-13. (IF :4.182)
141.Kuo HP, Lee DF, Chen CT, Liu M, Chou CK, Lee HJ, Du Y, Xie X, Wei Y, Xia W, Weihua Z, Yang JY, Yen CJ, Huang TH, Tan M, Xing G, Zhao Y, Lin CH, Tsai SF, Fidler IJ, Hung MC. ARD1 Stabilization of TSC2 Suppresses Tumorigenesis Through the mTOR Signaling Pathway. Science Signaling. 2010 Feb 9;3(108). ( IF: 6.354)
142.Sher YP, T-F Tzeng, S-F Kan, J Hsu, X Xie, Z Han, W-C Lin, L-Y Li, and M-C Hung. Cancer Targeted Gene Therapy of BikDD Inhibits Orthotopic Lung Cancer Growth and Improves Long-Term Survival. Oncogene. 2009;28(37):3286-95. (IF :7.216).
143.Yang, J-Y., Zong, C.S., Xia, W., Yamaguchi, H., Ding, Q., Xie, X., Lang, J-Y., Lai, C-C., Chang, C-J., Huang, W-C., Huang, H., Kuo, H-P., Lee, D-F., Li, L-Y., Lien H-C., Cheng, X, Chang, K-J., Hsiao, C-D., Tsai, F-J., Tsai, C-H., Sahin, AA., Hortobagyi, GN., Yu, D., Muller, WJ., Mills, GB., and Hung, M-C. Erk promotes tumorigenesis by inhibiting Foxo3a via MDM2-mediated degradation. Nature Cell Biology. 2008; 10(2):138-48.. (IF:19.47).
144.Ding, Q., He, X., Xia, W., Hsu, J-M., Chen, C-T., Li, L-Y., Lee, D-F., Yang, J-Y., Xie, X., Liu, J-C., and Hung, M-C. Mcl-1 inversely correlates with GSK-3β activity and associates with poor prognosis in human breast cancer. Cancer Research, 2007;67(10):4564-71. (IF:8.234).
145.Seethammagari, M. R., Xie, X., Greenberg, N. M., and Spencer, D. M. (2006). EZC-prostate models offer high sensitivity and specificity for noninvasive imaging of prostate cancer progression and androgen receptor action. Cancer Res 2006;66, 6199-6209. (IF: 8.234).
146.Ou-Yang, F., Lan, K. L., Chen, C. T., Liu, J. C., Weng, C. L., Chou, C. K., Xie, X., Hung, J. Y., Wei, Y., Hortobagyi, G. N., Hung, M-C. Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells. Cancer Res 2006; 66, 378-384. (IF:8.234).
147.Day, C. P., Rau, K. M., Qiu, L., Liu, C. W., Kuo, H. P., Xie, X., Lopez-Berestein, G., Hortobagyi, G. N., and Hung, M. C.. Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model. Cancer Gene Ther 2006;13, 706-719. (IF: 3.744).
148.Tuttle, D. L, CR Coberley, X Xie, ZC Kou, JW Sleasman, and MM Goodenow. Effects of human immunodeficiency virus type 1 infection on CCR5 and CXCR4 coreceptor expression on CD4 T lymphocyte subsets in infants and adolescents. AIDS Res Hum Retroviruses. 2004. 20(3): 305-13. (IF : 2.139).
149.Zhao T, XM Rao, X Xie, L Li, T Thompson, KM McMasters, and HS Zhou. Adenovirus with insertion-mutated E1A selectively propagates in liver cancer cells and destroys tumors in vivo. Cancer Res 2003;63(12):3073-8. (IF:8.234).
150.M Drozdzik, C Qian, X Xie, JJ Lasarte, J Prieto. Gene therapy of hepatoma model by combination of adenovirus expressing the HSV thymidine kinase and interleukin-12. J Hepatology. 2000; 32(2): 379-86. (IF:9.334)
151.Mazzolini G, C Qian, I Narvaiza, M Barajas, F Borras-Cuesta X Xie, M Duarte, I Melero and J Prieto. Adenoviral gene transfer of Interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effect level. Human Gene Therapy 2000; 11:113-25. (IF: 4.829).
152.Lasarte JJ, FJ Corrales, N Casares, A Lopez-Diaz de Cerio, C Qian, X Xie, F Borras-Cuesta, and J Prieto. Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministrered antigen: the role of nitric oxide. J Immunology, 1999; 162:5270-5277. (IF:5.745)
153.Mazzolini G, C Qian, X Xie, Y Sun, JJ Lasarte M, Drozdzik, J Prieto. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Therapy, 1999; 6(6): 514-22. . (IF: 3.744)
154.Lau J Y-N, X Xie, MMC Lai, and PC Wu. Apoptosis and viral hepatitis. Seminar in Liver Disease 1998; 18(2):169-176.(IF : 7.053)
（中文论文25篇）：
155.黄晓嘉,唐海林,谢小明.程序性死亡配体1 在三阴性乳腺癌中的研究进展. 中华乳腺病杂志(电子版) 2017；11（4）：234-237
156.谢新华，韦尉东，孔亚楠，郭姣丽，吕宁，唐军，肖祥胜，谢小明*。药物代谢酶CYP2D6在他
莫西芬个体化治疗中的研究进展。中华乳腺病杂志。 2011；5（5）：49-55
157.尹军,唐军,王曦,谢泽明,连臻强,谢小明,杨名添。乳晕下注射示踪剂行前哨淋巴结活检的可行性。 中华乳腺病杂志，2008，2（5）：514-519。
158.夏良平，周菲菲，杨名添，谢小明.乳腺癌中基因标签研究的共性问题.国际肿瘤学杂志, 2009.36(4)。
159.韦尉东 谢小明. 后曲妥珠单抗时代的乳腺癌靶向治疗.广东医学。2010；31（2）. 133-136。
160.吕宁，孔亚楠，谢小明，韦尉东。乳腺癌抗-EGFR 治疗的机制和临床进展。广东医学。2010；31（21）2874-2876。
161.肖祥胜 李峻 王曦 韦尉东 唐军 刘鹏 谢小明。青年乳腺癌209例生存分析。中国医师进修杂志。 2010.
162.谢小明, 苏先狮, 张铮. 逆转录-套式-聚合酶链反应检测HCV RNA正链和负链及与肝细胞癌的关系. 中华传染病杂志. 1996; 14(4): 211-213
163.蔡太生，谢小明，王丽. 慢性乙肝病人的心理健康状况及相关因素的调查分析. 中国临床心理学杂志. 1996; 4(2): 111-113
164.谢小明，苏先狮, 张铮. 丙型肝炎病毒与肝细胞癌关系的分子生物学研究进展. 国外医学：生理病理科学与临床分册. 1995; 15(2): 106-108
165.谢小明, 苏先狮, 张铮, 郑宣鹤, 杨旭, 曾晓波, 陈一德, 李良友, 刘国清, 皮执民, 黄江生.肝癌患者丙型肝炎病毒感染的研究. 中国现代医学杂志. 1994; 4(1): 27-28
166.谢小明, 苏先狮,张铮, 郑宣鹤, 陈一德. 聚合酶链反应研究丙型肝炎病毒与肝癌的关系. 中华传染病杂志.1994; 12(3): 169-170
167.谢小明, 苏先狮, 陈一德, 李良友, 郑宣鹤, 曾滑, 吴卫民, 刘远芳. 肝癌患者血清乙型肝炎病毒标志物和抗丙型肝炎病毒抗体的检测及其相互关系. 医学临床研究. 1994; 11(2): 64-66
168.郑煜煌, 金一平, 谢小明, 张雪梅, 蒋芳清, 王计全 , 易长庚. 甲型肝炎患者外周血T淋巴细胞集落和T淋巴细胞亚群的观察. 中华传染病杂志. 1994; 12(1): 49-50
169.谢小明. 无症状供血者和慢性丙型肝炎患者血清HCV RNA的定量研究. 国际流行病学传染病学杂志. 1993; 20(5): 228-228
170.谢小明, 郑煜煌, 刘远芳, 金一平, 刘雪梅, 蒋芳清, 王计垒, 易长庚. 甲型肝炎患者外周血T淋巴细胞亚群的观察. 医学临床研究. 1993; 10(5): 260-261
171.谢小明, 苏先狮, 张铮, 陈一德, 李良友, 郑宣鹤, 刘国清, 皮执民, 周健平, 齐海智. 乙型、丙型和丁型肝炎病毒与肝细胞癌岛关系. 中西医结合肝病杂志. 1993;3 (2): 6-7
172.苏先狮, 谢小明, 陈一德, 杨观生. 湖南供血员和肝病患者1272例血清抗HCV检测及甲乙丙丁各型肝炎混合感染的研究. 临床肝胆病杂志. 1993; 9(1): 10-11
173.苏先狮, 郑宣鹤, 钱焕英, 王谷丰, 邓纯, 刘丽霞, 彭兰莎, 谢小明. 肝脏刺激生长素(HSS)治疗病毒性肝炎300例的临床研究. 临床肝胆病杂志. 1992; 8(3): 126-127
174.郑煜煌, 谢小明. 甲型肝炎患者外周血T淋巴细胞集落的观察. 广西医学, 1992; 6(6): 4-5
175.郑宣鹤, 龚国忠, 何艳, 黄道芩, 谢小明.急性肝炎重型并发急性容血性贫血和类白血病反因二例. 中华传染病杂志. 1991; 9(1): 32-33
176.郑煜煌, 谢小明, 张永红, 何艳. 病毒性肝炎患者中肥达反应的动态观察. 医学临床研究. 1990; 7(3): 167-169

主编专著
1.谢小明等。乳腺癌个体化治疗(第十八章)《肿瘤个体化医学原则》,人民卫生出版社。 2013.p 227-241
2.谢小明等。乳腺疾病相关的分子生物学(第三章第四节)《现代乳腺外科》, 人民卫生出版社2014.p92-103.
3.谢小明等。乳腺癌的危险因素(第14章)《乳腺疾病学》, 人民卫生出版社2017.p155-164.
4.Mien-Chie Hung, JL Hsu, CH Chao, Xiaoming Xie. Advances in Liposome-Based Targeted Gene Therapy of 《Cancer Recent Advances in Cancer Research and Therapy》，Elsevier，18 May 2012
5.Wang Z, Wang N, Liu P, Xie X. AMPK and Cancer. EXS. 2016;107:203-226.

部分国际会议（*为第一作者或通信作者文摘）：
*1. The 8th International Conference on Viral Hepatitis. Xie X, X Su, et al. A comparative study of on the relationship of HBV, HCV and HDV with hepatocellular carcinoma. Beijing, China. 1993北京
*2. The annual meeting of the Association for the Study of Liver Diseases. Xie, et al. In vivo gene transfer to hepatocullular carcinoma in experimental animal models by adenoviral vector. London, 1996. 伦敦
*3. The 2rd annual meeting of the Europe Society of Gene Therapy. X Xie, M Idoato and J Prieto. In vivo gene transfer to hepatocullular carcinoma by adenoviral vector. London, 1998. 西班牙
*4. The 48th annual meeting of the American Association for the Study of Liver Diseases. Xie X, CE Forsmark and JYN Lau. Feasibility of adenoviral-mediated gene delivery through EGFP: the effect of bile and pancreatic juice. Chicago, USA, 1997. 芝加哥
*5. The 6th Conference on retroviruses and Opportunistic Infections. Xie X, D Turtle, J.W. Sleasman and M.M. Goodenow . CD4 T lymphocytes that coexpress CD45RO and CD45RA are the primary target cells for infection by HIV-1. Chicago, USA, 1999. 芝加哥
*6. The 3rd annual meeting of the American Society of Gene Therapy, Xie X, Spencer D. Robust prostate cell-specific expression based on human kallikrein 2(hK2) has been developed for targeted gene therapy. Denver, USA, 2000. 丹佛
*7. The 4th annual meeting of the American Society of Gene Therapy, Xie X, Spencer D. Adenovirus-mediated tissue-targeted expression of a caspase 9-based artificial death switch for the treatment of prostate cancer. Seattle, USA, 2001. 西雅图
*8. The 5th annual meeting of the American Society of Gene Therapy, Xie X, Spencer D. Novel gene therapy for prostate cancer: in vivo-targeted expression of the E.Coli purine nucleoside phsophorylase gene by adenoviral delivery. Boston, USA, 2002. 波士顿
*9. The 6th annual meeting of the American Society of Gene Therapy, Xie X, Spencer D. Novel prostate model. Washington DC, USA, 2003. 华盛顿
*10. The 8th annual meeting of the American Society of Gene Therapy, Xie X, et al. Targeted prostate cancer gene therapy (oral presentation). St. Louis, USA, 2005圣路易斯
*11. The 10th annual meeting of the American Society of Gene Therapy, Xie X, et al. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models (oral presentation). Seattle, USA, 2007. 西雅图
*12. IMPcCT (Innovative Minds in Prostate Cancer Today), Department of Defense. Xie X, et al. Targeted expression of BikDD cures AIPC and ADPC in noninvasive imaging models. Atlanta, USA, 2007.
13. The 5th Chinese Conference on Cancer and International Gene Therapy. Shijianzhuan, Hebei,China, 2008.
*14. The 15th World Congress on Breast Diseases and 3rd Shanghai Breast Cancer Symposium. Shanghai, China, Oct. 2008. 上海
15. The San Antonio Breast Cancer Symposium at An Antonio, USA. Dec 10-15. 2008. 圣奥东尼奥
*16. The 5th Conference on Cancer Translational Research. Xie et al. “VISA” nanopaticles to breast cancer. Feb. 19-21. 2009. Macau.
17. The St Gallen Oncology Conference in Switzerland. March 11-15, 2009. 瑞士
18. The 45th Annual Meeting of the American Society of Clinical Oncology. Orlando, USA. May 28-June 3. 2009. 奥尔兰多
*19. the 14th Annual Scientific Symposium of Hong Kong Cancer Institute-Breast Cancer Symposium. Xie X, et al.“VISA” nanopaticles targeting to breast cancer. Nov. 11-14. Hong Kong. 香港
*20. The San Antonio Breast Cancer Symposium at San Antonio. Xiaoming Xie, et al. “VISA” nanopaticles to breast cancer. USA. Dec 9-14. 2009. 圣奥东尼奥
*21. The 46th Annual Meeting of the American Society of Clinical Oncology. “VISA” nanopaticles to breast cancer in animal models. Chicago, USA. June 3-June 8. 2010. 芝加哥
*22. The San Antonio Breast Cancer Symposium at San Antonio. Xiaoming Xie, et al. “VISA” nanopaticles targeting to breast cancer in vitro and in animal models. USA. Dec 8-12. 2010. 圣奥东尼奥
*23. The 47th Annual Meeting of the American Society of Clinical Oncology. “VISA” nanopaticles to breast cancer in animal models. Chicago, USA. June 3-June 8. 2011. 芝加哥
*24. The 16th Annual Scientific Symposium of Hong Kong Cancer Institute-Breast Cancer Symposium. Xie X, et al.“VISA-miRNAs” nanopaticles target to breast cancer. Nov. 4-6. Hong Kong. 香港
*25. The San Antonio Breast Cancer Symposium at San Antonio. Xiaoming Xie, et al.. USA. Dec 6-10. 2011. 圣奥东尼奥
*26. The 48th Annual Meeting of the American Society of Clinical Oncology. “VISA” nanopaticles to breast cancer in animal models. Chicago, USA. June 1-5. 2012. 芝加哥
*27. The 2nd International Conference on Cell Science and Stem Research. “VISA-BikDD” and “VISA-miRNA” nanoparticles targeting to breast cancer and breast cancer stem cells. Invited Speaker. San Antonio. OMICS Group Conference. USA. Nov. 14-15, 2012. 圣奥东尼奥
*28. The San Antonio Breast Cancer Symposium at San Antonio. VISA-miRNA and VISA-BikDD nanopaticles targeting to breast cancer.. USA. Dec 4-8. 2012. 圣奥东尼奥
*29. China Cancer Conference. VISA- nanopaticles targeting to breast cancer stem cells. Beijing, Nov. 17-18. 2013. China
30. The 49th Annual Meeting of the American Society of Clinical Oncology. Chicago, USA. June , 2013. 芝加哥
*31. The San Antonio Breast Cancer Symposium at San Antonio. VISA nanopaticles targeting to breast cancer.. USA. Dec 8-12. 2013. 圣奥东尼奥
32. The 50th Annual Meeting of the American Society of Clinical Oncology. Chicago, USA. June , 2014. 芝加哥
*33. The San Antonio Breast Cancer Symposium at San Antonio. VISA nanopaticles to breast cancer.. USA. Dec 8-12. 2014. 圣奥东尼奥
*34. The 51th Annual Meeting of the American Society of Clinical Oncology. Chicago, USA. June , 2015. 芝加哥
*35. The San Antonio Breast Cancer Symposium at San Antonio... USA. Dec 6-10. 2015. 圣奥东尼奥
*36. The 52th Annual Meeting of the American Society of Clinical Oncology. Chicago, USA. June , 2016. 芝加哥

新闻与报道：
1.纳米颗粒介导的VISA系统靶向治疗胰腺癌的主要研究成果，已发表2007年7月份的Cancer Cell
(IF:24.962）上。美国约翰霍普金斯大学医学院的胰腺癌专家Scott E. Ken教授，在 Science News 上评论：“这种治胰腺癌的方法是独一无二的，对胰腺癌既有非常强的疗效又非常特异”。美国ABC电视台认为“是胰腺癌治疗的一个重大突破”。来自美国、中国、俄国、德国、法国、西班牙、葡萄牙、意大利、荷兰、希腊、阿拉伯、韩国本等世界各的科学杂志和新闻媒体对该成就纷纷进行了200多次报道，并给予了高度的价。
2.中国医学论坛。2010.1
3.广东医师协会。 2010.9
4.南方都市报。2008.10
5.羊城晚报。 2012.3
6.凤凰网；番禺日报。广州首届公益创投项目“医路同行——关爱肿瘤病人”2014.
7.中央人民广播电台，2014
8.广州日报，吃火腿香肠会致癌? 不是天天吃大量吃就没事。2015
9.新快报。夜班工作会增加患乳腺癌风险?是真的。2015.
10.医师报。积极应对乳腺癌的复杂性与异质性
11.科技日报；健康报健康资讯；中国健康网。温州网 .执 着 的 追 求--记中山大学肿瘤防治中心乳腺科主任谢小明教授. 2016.2
12.羊城晚报。得了乳腺癌，还能圆当妈妈的梦吗？2017.
13.南方健客网。粉红健康用爱呵护。2017

部分获奖：
1.the 14th Hong kong Breast Cancer Conference 最佳奖, 2011, 香港.
2.AstraZeneca Award ($50,000). USA. 2005. 美国.
3.First prize, the 10th Annual Oncology Research Seminar. USA. 2001. 美国.
4.Travel Grant, the 6th Conference on retroviruses and Opportunistic Infections, USA. 1999. 美国.
5.The best oral presentation award. Terapia genica del hepatocarcinoma mediate la transferencia del gen la interlukina 12 y timidin kinasa mediada por adenovirus.Madrid, Spain. 1998. 西班牙.
6.Dr. Sir Q.W. Lee fellowship. USA. 1997. 美国.
7.Dr. Li Zhengbie’s Fellowship. China. 1994. 长沙.
8.Challenge Cup of China’s invention. China.1993. 挑战杯奖,上海.
9.<<湘楚青年科技名人录>> (1993年).
10.<<当代发明家成果辞典>> (1994年).
11.<<当代科学家与发明家大词典>> (1994年).
12.<<国际名人词典>> (第23版). 英国国际人物中心转记编辑出版，1994年. <<DICTIONARY OF INTERNATIONAL BIOGRAPHY>> (Twenty-third Edition).
13.Who's Who in the World? 2016 (33rd Edition).
14.2018 Albert Nelson Marquis Lifetime Achievement Award.

学会会员和社会兼职：
1.美国科学促进会（AAAS）(1998年)
2.美国基因治疗协会（ASGT）会员 （1999年)
3.美国 Sigma Xi 科学研究会会员（2000年)
4.美国癌症研究协会会员（AACR），(2004年)
5.美国临床癌症研究协会会员（ASCO）(2008年)
6.《Global Journal of Epidemiology and Public Health》共同主编
7.《Journal of Tumor》, Hong Kong. Associated editor,
8.美国《Journal of Cancer》编委
9.《Chinese Journal of Cancer》责任编委
10.《中华乳腺病杂志》编委
11.《肿瘤学杂志》编委
12.中华医学会肿瘤分会乳腺癌专业委员会委员
13.中华医学会整形外科学分会肿瘤整形外科学委员
14.国家自然科学基金委评审一审专家
15.国家自然科学基金委评审二审专家
16.国家博士后基金评审专家
17.中国研究型医院学会乳腺专业委员会常委
18.中国抗癌协会肿瘤代谢委员会委员
19.中国健康促进会乳腺癌防治专家
20.卫生部医疗服务标准专业委员会专家
21.教育部学位评审专家
22.广东省抗癌协会乳腺癌专业委员会常委
23.广东省医学会乳腺病分会常委
24.广东省医师协会乳腺专科医师工作委员会常委
25.广东省保健协会首席专家
26.广东省胸部肿瘤防治研究会乳腺癌专业委员会副主委
27.广东省自然科学基金委评审专家
28.广东省医学鉴定专家
29.广东省和谐医疗纠纷协调专家
30.广州市医疗事故技术鉴定专家
31.岭南名医
32.羊城好医生

更新日期：2019年5月24日